Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
about
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Missing HLA C group 1 ligand i ...... reduced toxicity conditioning.
@en
Missing HLA C group 1 ligand i ...... reduced toxicity conditioning.
@nl
type
label
Missing HLA C group 1 ligand i ...... reduced toxicity conditioning.
@en
Missing HLA C group 1 ligand i ...... reduced toxicity conditioning.
@nl
prefLabel
Missing HLA C group 1 ligand i ...... reduced toxicity conditioning.
@en
Missing HLA C group 1 ligand i ...... reduced toxicity conditioning.
@nl
P2093
P2860
P50
P356
P1476
Missing HLA C group 1 ligand i ...... reduced toxicity conditioning
@en
P2093
Alessandro Lo Russo
Arnon Nagler
Fabio Ciceri
Ivetta Danylesko
Maria Teresa Lupo Stanghellini
Massimo Bernardi
Noga Shem-Tov
Raffaella Greco
Ronit Yerushalmi
P2860
P304
P356
10.1002/AJH.24827
P577
2017-07-19T00:00:00Z